Bill

Bill > HB645


NH HB645

Relative to data collection and reporting requirements of the prescription drug affordability board.


summary

Introduced
01/21/2025
In Committee
03/03/2025
Crossed Over
Passed
Dead

Introduced Session

2025 Regular Session

Bill Summary

This bill requires reports issued by the prescription drug affordability board to describe the source of the data, encourages the use of memorandums of understanding between the board and state agencies regarding data collection, and directs the board to use data gathered by other agencies or entities whenever feasible to meet reporting requirements. The bill repeals certain drug price notification, confidentiality, and registration requirements. The bill also defines "data steward" for purposes of such data collection.

AI Summary

This bill modifies the powers and duties of the Prescription Drug Affordability Board (PDAB) in New Hampshire, focusing primarily on data collection and reporting requirements. The bill introduces a new definition for "data steward" as a person or entity responsible for collecting, managing, and reporting data while ensuring its quality. It expands the board's authority to identify and collect necessary data by working with existing state agencies to avoid redundant data collection, and requires reports to include information about data sources, limitations, and interpretation. The bill mandates that the board enter into memorandums of understanding (MOUs) with state agencies for data sharing and gives the board the power to collect data from third parties like drug manufacturers and pharmacy benefit managers. Additionally, the board can now enforce data collection through a compliance mechanism that allows it to assess fines of up to $500 per day (maximum $25,000) for entities that fail to provide requested data. The bill also updates reporting requirements to include actions taken by other states or the federal government that could help reduce prescription drug costs, and removes some previous provisions related to drug price notifications and confidentiality. Notably, the bill does not provide additional funding but anticipates potential revenue from non-compliance fees and expects some increased administrative costs for the board.

Committee Categories

Health and Social Services

Sponsors (4)

Last Action

Lay HB 645 on Table (Rep. Osborne): Motion Adopted Voice Vote 03/13/2025 House Journal 8 P. 78 (on 03/13/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...